Mechanisms of Angiogenesis Process after Pancreatic Islet Cell
Transplantation: Role of Intra-islet Endothelial Cells
Siddharth Narayanan, Gopalakrishnan Loganathan, Maheswaran Dhanasekaran, Michael J Hughes, Stuart K Williams and Appakalai N Balamurugan*
Department of Surgery, University of Louisville, Kentucky, USA
- *Corresponding Author:
- Appakalai N Balamurugan
Clinical Islet Cell Laboratory
Center for Cellular Transplantation
Cardiovascular Innovation Institute
Department of Surgery, University of Louisville
Louisville, KY, USA
E-mail: [email protected]
Received Date: December 07, 2016; Accepted Date: December 23, 2016; Published Date: January 02, 2017
Citation: Narayanan S, Loganathan G, Dhanasekaran M, Hughes MJ, Williams SK, et al. (2017) Mechanisms of Angiogenesis Process after
Pancreatic Islet Cell Transplantation: Role of Intra-islet Endothelial Cells. J Transplant Technol Res 7: 171. doi:
Copyright: © 2017 Narayanan S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Journal of Transplantation Technologies & Research
Angiogenic sprouting is a complex, multi-step process involving highly integrated cell behaviours, initial interaction with the environment and signalling pathways. Endothelial cells (ECs) are central to the angiogenic process, with recent insights establishing how these cells communicate with each other and with their microenvironment to form branched vascular networks. Using pancreatic islets as a model for vascularized tissue, this review will present a general overview of EC behaviour dynamics in sprouting angiogenesis, particularly focusing on the interplay between VEGF and Notch pathways. A better understanding of molecular mechanisms associated with intra-islet EC cross-talk and its micro-environment may present exciting new perspectives on islet graft to host revascularization and in supporting islet graft survival.
Transplantation; Endothelial cells; Angiogenesis;
Pancreatic islets are highly vascularized and receive 10% of the
pancreatic blood flow despite comprising of only 1-2% of the overall
tissue mass . Islets represent endocrine “island” clusters, embedded
and scattered within large amounts of exocrine acinar tissue . Most
islets are irregularly shaped spheroids with a size distribution ranging
from 50–200 μm, composed of 800–3,000 cells. In the context of islet
studies and transplantation, 1 islet equivalent (IEQ) is often considered
as a size of 150 mm, consisting of an average 2,500 cells. The cellular
components of the islet include β-cells with the remainder of the islet
comprised of other endocrine cells (including glucagon-secreting α-
cells, somatostatin secreting δ-cells, pancreatic polypeptide-secreting
γ-cells, and ghrelin-producing ε-cells), as well as ECs and support cells
such as pericytes [3-12]. Species heterogeneity exists with respect to
cellular composition of islets. Rodent islets are primarily composed of
β-cells located in the center with other cell types in the periphery,
human islets exhibit interconnected α- and β-cells [3-13,14]. β-cell, the
central regulator of glucose homeostasis is the largest cellular
component of islets in most species [12,13]. Vascular endothelial cells
represent a major cell type present in islets and these cells are
organized into a highly regulated and morphologically unique
microcirculation. Studies using vascular corrosion casts have shown
that 1-3 arterioles feed larger islets . The capillary network within
islets is about five times denser in comparison with exocrine tissue
. The capillary wall is composed of a permeable layer of ECs and
contain ten times more fenestrae than ECs present in the exocrine
pancreas [17,18]. Rapid and adequate revascularization is critical for
survival and function of transplanted islets [19-21]. Unlike whole
organ transplantation where revascularization occurs through surgical
anastomosis of vessels, the revascularization of islets requires the
formation of vessel patencies either through inosculation of host and
recipient microvessels or through neo-vessel penetration into the islet.
The return of islet function depends on reestablishment of new vessels
within islet grafts to derive blood flow from the host vascular system
[22,23]. Transplanted islet grafts initially have a significant reduction in
vascular supply and low oxygen tension in comparison to normal islets
[24-26]. The human islet isolation technique completely severs the islet
vasculature [20,27], the enzymatic digestion step contributing towards
partially disrupting intra-islet ECs [22,28,29]. Revascularization is an
important process for adequate engraftment of islets. Prevascularizing
islets prior to transplantation could potentially improve islet
survivability and function by aiding islet-to-host inosculation .
Studies involving cell and tissue engineering approaches have
considered factors such as pancreatic islet size-dependency , use of
stem cells [32-35], endothelial progenitor cell derived microvesicles
, creating engineered vascular beds and hydrogels [37-39] and
repurposed biological scaffolds  to improve islet revascularization
potential. The angiogenic capacity of islet ECs has been previously
determined . These cells have been shown to support
revascularization of fresh islets by participating in the early processes
of vessel formation [30,42]. Unpublished data from our lab
demonstrates that fresh islets, immediately after isolation, are capable
of forming peri-islet vessels in a 3D-gel construct (Figure 1). The initial
molecular events by which intra-islet ECs result in the formation of
such vessels have not yet been explored. This review will focus on the
VEGF-Notch signalling pathways and their associated molecular
regulation which have been well characterized and shown to play key
roles in endothelial crosstalk critical to proper vessel sprouting.
Figure 1: Islet sprout monitoring in group of human islets in time
Regulation of angiogenesis
VEGF family: critical regulators of angiogenesis: The family of
VEGF (vascular endothelial growth factor) ligands and their receptors
are major regulators of sprouting angiogenesis [43-46]. VEGFs are
critical, as they regulate vessel formation during embryonic
development, play a major role in wound healing and in maintaining
vessel homeostasis in adult organisms. In addition, impaired vessel
function resulting from defects in VEGF ligands or receptors is the
cause of many diseases. VEGF was originally described as vascular
permeability factor (VPF), an activity released by tumor cells that
promotes vascular leakage [43,47-56]. VEGF secretion is stimulated by
tumor, hypoxia, low pH and many other factors. The VEGF binds to its
receptor (VEGFR) located on the blood vessel ECs. The ECs upon
activation produce enzymes and other molecules for EC growth and
proliferation. Other effects include mobilization of endothelial
progenitor cells from bone marrow, increased vascular permeability
and tissue factor induction. The VEGF family comprises seven secreted
glycoproteins that are designated VEGF-A, VEGF-B, VEGF-C, VEGFD,
VEGF-E, placental growth factor (PlGF) and VEGF-F [57-59].
VEGF-A, the most well studied factor within the VEGF family, is
expressed in the extra-embryonic endoderm and mesoderm as blood
islands, and within the intra-embryonic endoderm at E8.5  (Table
|Type of VEGF
||Role in regulating/modulating ECs
||Most potent pro-angiogenic protein described to date, implicated in both vasculogenesis and angiogenesis. It induces proliferation, sprouting and tube formation of ECs.
|Is a potent survival factor for ECs and has been shown to induce the expression of anti-apoptotic proteins in these cells.
|Causes vasodilatation by inducing the endothelial nitric oxide synthase and so increasing nitric oxide production.
|VEGFR-A binds many receptors on hematopoietic stem cells (HSCs), monocytes, osteoblasts and neurons; induces HSC mobilization from the bone marrow, monocyte chemo-attraction and osteoblast-mediated bone formation
|Many cytokines including platelet-derived growth factor, basic fibroblast growth factor, the epidermal growth factor and transforming growth factors induce VEGF-A expression in cells.
||Several reports suggest that VEGF-B may modulate cell proliferation and vessel growth. Conditioned medium from transfected cells expressing VEGF-B stimulates DNA synthesis in endothelial cells.
|Shown to play a central role in cardiac development.
||The mature form of VEGF-C induces mitogenesis, migration and survival of ECs
|VEGF-C mRNA transcription is induced in ECs in response to pro-inflammatory cytokines (IL-β).
|Promote lymphatic vessel development and may also contribute to angiogenesis.
||The mature human VEGF-D is mitogenic, angiogenic and lymphogenicin vivo
|Stimulates growth of vascular and lymphatic ECs by signaling through the tyrosine kinase receptors (VEGFR-2, VEGFR-3)
|Promote lymphatic vessel development and may also contribute to angiogenesis.
||Highly specific isoform that acts only on the endocrine gland endothelial cells.
| VEGF-E is a potent angiogenic factor and data strongly indicates that the activation of VEGFR-2 alone can stimulate angiogenesis efficiently.
||Originally identified in the placenta; occurs at low levels in the embryo and adult and has primarily been studied in pathological conditions where it is thought to stimulate angiogenesis in coordination with VEGF-A.
Table 1: Types of vascular endothelial growth factors (VEGFs) with evidence demonstrating their involvement in regulating endothelial cells.
VEGF family members interact with three main receptors,
VEGFR-1 (FLt-1), VEGFR-2 (KDR in humans and Flk-1 in mouse)
and VEGFR-3 (Flt4), all tyrosine kinase receptors and members of the
PGDF receptor family. VEGF receptors possess an extracellular
domain consisting of immunoglobulin repeats responsible for VEGF
binding and intracellular tyrosine kinase domains. VEGF binding to its
receptor leads to receptor dimerization and activation of receptor
tyrosine kinases by autophosphorylation. This leads to several biologic
effects on endothelial cells. The VEGF receptor transmembrane
tyrosine kinases, which upon binding of their ligands to the
extracellular domain of the receptor, activate a cascade of downstream
proteins after the dimerization and autophosphorylation of the
intracellular receptor tyrosine kinases. VEGFR-2 appears to be the
main receptor responsible for mediating the proangiogenic effects of
VEGF-A [57,79,80]. VEGF-A and its receptors VEGFR-1 and
VEGFR-2 are expressed early in embryonic development (Table 2).
|Type of VEGFR
||Role in regulating/modulating endothelial cells (ECs)
||Expressed in ECs as well as osteoblasts, monocytes/macrophages, placental trophoblasts, renal mesangial cells and also in some hematopoietic stem cells (HSCs).
|VEGFR-1 expression is upregulated by hypoxia (HIF1 dependent mechanism).
|Has an active functional role and participates in monocyte migration, recruits EC progenitors and increases adhesive properties of natural killer cells.
||Undergoes dimerization and strong ligand-dependent tyrosine phosphorylation in intact cells and results in a mitogenic, chemotactic, and pro-survival signal.
|Y1175 and Y1214 are the two major VEGF-A-dependent autophosphorylation sites in VEGFR-2. However, only autophosphorylation of Y1175 is imperative for VEGF dependent EC proliferation.
|In addition to the ECs, VEGFR-2 is also expressed on neuronal cells, osteoblasts, megakaryocytes and HSCs.
|It is down-regulated in the blood vascular ECs, and is again up-regulated in angiogenic blood vessels.
|Sequestration of VEGF-A results in down-regulation of VEGFR-2 and in apoptotic death of some capillary endothelial cells in vivo.
|It is an early marker of endothelial and hematopoietic precursor cells in blood islands.
||Recently shown to be strongly modulated by Notch upregulating angiogenesis in absence of VEGF-VEGFR2 signalling.
|VEGFR-3 is up-regulated on blood vascular ECs in pathologic conditions such as in vascular tumors and in the periphery of solid tumors.
|Widely distributed in vascular tumors and can be considered as a marker of endothelial cell differentiation of vascular neoplasms.
|is down-regulated in vivo at sites of endothelial cell–pericyte/smooth muscle cell contacts; suggesting that VEGFR-3 signaling is important in nascent blood vessels, and it becomes redundant as the vessels mature. In humans, VEGFR-3 expression was upregulated in blood vessel endothelium in chronic inflammatory wounds.
Table 2: An overview of vascular endothelial growth factor receptors and their roles in regulating endothelial cells.
Notch signaling: In addition to the VEGF receptor tyrosine kinases
and their ligands, several recent studies demonstrate the importance of
Notch signalling components such as ligands Dll4 (Delta-like ligand 4),
Jagged-1 and Notch1 in EC specification during formation of a
functional vascular network [96-99]. In mammals there are 5 DSL
(Delta Serrate Lag-2) ligands: Delta-like 1 (Dll1), Delta-like 3 (Dll3),
Delta-like 4 (Dll4), Jagged-1 (Jag1) and Jagged-2 (Jag2). These ligands
are type1 cell-surface proteins with multiple tandem epidermal growth
factor (EGF) repeats in their extracellular domains (ECDs). DSL
ligands bind to Notch receptors, which are large, single pass, type1
transmembrane receptors. There are 4 known Notch receptors, Notch1
to Notch4. Binding of a DSL ligand to the ECD of the Notch receptor
(NECD) triggers a series of proteolytic cleavages of Notch, first by a
member of the disintegrin and metalloproteases (ADAM) family
within the juxta-membrane region, followed by γ-secretase within the
transmembrane domain (Table 3). The Notch receptors, ligands, and
several signaling pathway components have been identified in
endothelial cells in vitro and in vivo , during development and tumor
||Pathway component expressed by ECs
||Notch1 and Notch4
||DSL ligands Dll1, Dll4, Jag1 and Jag2
|Key Notch signaling components
||Rbpj, Hey1, Hey2, Maml1, Numb and Nrarp
Table 3: Notch pathway components expressed in endothelial cells.
Functional studies using gene targeting in mice, mutagenesis and
knockdown in zebrafish, and biochemical analysis in cultured
endothelial cells have demonstrated that Notch signaling plays a fundamental role in many aspects of endothelial cell biology during
angiogenesis  (Table 4).
||Notch component(s) involved
|Tip/stalk cell specification
|Matrix production/assembly and cell adhesion
Table 4: Evidence for the role of Notch components involved in endothelial cell function.
EC phenotypes: Interplay between VEGF and Notch signalling in
regulating EC sprouting. An exciting breakthrough within angiogenic
research in the past decade has been the identification of different EC
phenotypes with different cellular fate specifications that are key in
forming a vessel branch . Leading the trail are ‘tip cells’ which
sense and respond to guidance cues. ‘Stalk cells’ follow behind the tip
cells and elongate the stalk of the sprout by proliferating, forming
junctions, modulating the extracellular matrix and forming a lumen.
‘Phalynx cells’, the most quiescent of the ECs, line vessels once new
vessel branches have formed. These cells form a monolayer, are covered
by pericytes, attached via tight junctions, and strongly held by a robust
basement membrane. Phalynx cells are engaged in optimizing blood
flow, tissue perfusion and oxygenation [123-125].
Specification of ECs into tip and stalk cells bearing different
morphologies and functional properties is central to sprouting
initiation [113,126]. Vessel networks, while expanding, require ECs to
undergo frequent cycles of sprouting and branching. This results in
dynamic transitions between the two cell phenotypes [113,126]. Tip
cells express high levels of Dll4, platelet derived growth factor-b
(PDGF-b), unc-5 homolog b (UNC5b), VEGFR 2/3 and has low levels
of Notch signalling activity [98,99,103,127,128]. Stalk cells produce
fewer filopodia, are more proliferative, form tubes, branches and a
vascular lumen, establish junctions with neighbouring cells and
synthesise basement membrane components [113,129]. Tip cell
migration depends on a VEGF gradient migrating outward from
parent vessel whereas stalk cell proliferation is regulated by VEGF
concentration [127,130]. VEGF stimulates tip cell induction and
filopodia formation via VEGFR2 (abundant on filopodia), whereas
VEGFR2 blockade is associated with sprouting defects . VEGFR1
expression is induced by Notch signalling to reduce VEGF ligand
availability preventing tip cell outward migration. VEGFR1 is
predominantly (Figure 2) expressed in stalk cells and is involved in
guidance and limiting tip cell formation. Loss of VEGFR1 results in
increased sprouting and vascularization [131,132].
Figure 2: Islet sprout monitoring in single human islets in time lapse
Notch appears to act as a negative feedback mechanism to regulate
VEGF signaling. This regulation may explain the observation that
decreased VEGFR-2 allows for local differentiation of endothelial tip
cells prior to sprout initiation with VEGF action on tip cells leading to
increased Dll4 expression and activation of Notch signaling, which in
turn downregulates VEGFR-2 in neighboring stalk cells . Tip cells
with higher VEGFR-2 expression will, therefore, readily respond to
VEGF while stalk cells with fewer receptors will be less responsive.
Interestingly, tip cells do not proliferate in response to VEGF, but
rather form filopodia and migrate in the direction of the VEGF
gradient. It is the stalk endothelial cells of the growing capillary branch
that proliferate .
In mouse and zebrafish angiogenesis, VEGFR3 is strongly expressed
in the leading tip cell and is downregulated by Notch signalling in the
stalk cell [98,133]. Notch1 and Notch4 and the three Notch ligands JAG-1, Dll1 and Dll4 are expressed in ECs for the induction of arterial
cell fate and for the selection of endothelial tip and stalk cells during
sprouting angiogenesis . Activation of Notch signalling reduces
while its loss induces sprouting. Notch-1 deficient ECs adopt tip cell
characteristics [97,98,129] whereas in stalk cells, activation of Notch by
Dll4 leads to downregulation of VEGFR-2 and -3 [101,135]. Cells
dynamically compete for tip position utilizing differential VEGFR
levels, as cells with higher VEGFR signalling produces more Dll4 and
therefore inhibit their neighbouring cells. VEGF has been shown to
induce the expression of Dll4 and Notch signaling . Elevated Dll4
and VEGFR-2 expression was detected in tip cells compared to
neighboring stalk cells . Blockage of VEGF, in animal models,
caused a decrease of Dll4 in vessels and inhibited sprouting 
whereas administration of VEGF induced Dll4 expression . Notch
signaling also influences VEGF receptor expression, leading to the
downregulation of VEGFR-2, as evidenced by decreased VEGFR-2
levels after Notch activation in ECs and in Dll4-deficient mice
[99,109]. Endothelial Notch activation regulates the expression of
different VEGFRs (VEGFR1, 2, and 3) as well as the co-receptor Nrp1
[46,93,97,98,103,114,115,137]. Dll4 activates Notch in adjacent cells,
which suppresses the expression of VEGF receptors and thereby
restrains endothelial sprouting and proliferation [98,99,113,138].
Notch activation in HUVECS leads to VEGFR1 mRNA induction
[120,139]. In contrast, VEGFR2 and Nrp1 mRNA is markedly reduced
by Notch activation in HUVECs [137,140,141], indicating that Notch
signaling is able to regulate how the ECs respond to VEGF. The Notch
and VEGF signaling appear to be intimately associated in
angiogenesis. It has been shown that Notch signalling acts downstream
of the VEGF pathway during physiological and pathological
angiogenesis [115,140,142-144], suggesting that VEGF pathway
controls expression of different Notch components (Table 5).
||Recently identified for sprouting angiogenesis
|MEF2 transcription factors
|Foxo1 transcription factor
|ROS and redox events
Table 5: Novel regulators recently identified to play a role in angiogenesis (ECs/VEGF/Notch pathways).
Conclusions and Future Perspectives
Significant progress has been made in our understanding of
importance of angiogenesis in health and disease but our
understanding of coordinated events that result in vessel branching
and vessel inosculation remains incomplete. We are just beginning to appreciate the interplay of other signalling pathways such as Wnt and
BMP in regulating vessel sprouting. Angiogenesis is a complex, multistep
process. Key to this process are ECs, which are pivotal to sprouting
angiogenesis and have been implicated in many diseases [60,161-163].
It has been shown that EC proliferative capacities can be stimulated by
various inducers [41,42,164,165]. A variety of in vivo and in vitro models for understanding EC behaviour during angiogenesis at the
cellular level have been derived from systems such as rabbit cornea
, developing mouse retina , intersegmental vessel growth in
zebrafish  and using ECs embedded in collagen or fibrin gels
In the last two decades, focus has been paramount on the study of
human pancreatic islets, its isolation techniques and in improving islet
yield and function because of it critical involvement in debilitating
diseases such as Type-1 diabetes and chronic pancreatitis. The dense
vasculature within the pancreas is an important determinant in the
physiology and disease of islets. The pancreatic islets is an ideal model
‘tissue’ to learn more about microvasculature and in this context the
study of ECs within islets has potential benefits. The islet EC model
represents an excellent platform to better understand molecular
mechanisms associated with vessel sprouts, an important but greatly
understudied area within islet research. Crosstalk of ECs with other
islet cells, such as the β-cells has been evaluated [171-175] particularly
in increasing β-cell mass and thereby insulin production. Moreover, a
number of factors which may potentially improve islet transplantation involve ECs. Vascular ECs of the embryonic aorta have been shown to
induce the development of endocrine cells from pancreatic epithelium
in mouse [176,177] and overexpression of VEGF-A in transplanted
mouse islets was shown to improve insulin secretion and blood glucose
regulation in recipient mice [165,178]. Utilizing intra-islet ECs as a
model to better understand mechanisms associated with sprouting
angiogenesis is likely to generate exciting new hypotheses and offer
new insights of how transplanted islets can reestablish vasculature
more efficiently and successfully.
- Chandra R, Liddle RA (2009) Neural and hormonal regulation of pancreatic secretion. CurrOpinGastroenterol 25: 441-446.
- Stendahl JC, Kaufman DB, Stupp SI (2009) Extracellular matrix in pancreatic islets: relevance to scaffold design and transplantation. Cell Transplant 18: 1-12.
- Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, et al. (2005) Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J HistochemCytochem 53: 1087-1097.
- Khandekar N, Berning BA, Sainsbury A, Lin S (2015) The role of pancreatic polypeptide in the regulation of energy homeostasis. Mol Cell Endocrinol 4181: 33-41.
- Katsuura G, Asakawa A, Inui A (2002) Roles of pancreatic polypeptide in regulation of food intake. Peptides 23:323-329.
- Yada T, Damdindorj B, Rita RS, Kurashina T, Ando A, et al. (2014) Ghrelin signalling in beta-cells regulates insulin secretion and blood glucose. Diabetes ObesMetab 1: 111-117.
- DiGruccio MR, Mawla AM, Donaldson CJ, Noguchi GM, Vaughan J,et al. (2016) Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets. MolMetab 5: 449-458.
- Wierup N, Svensson H, Mulder H, Sundler F (2002) The ghrelin cell: A novel developmentally regulated islet cell in the human pancreas. RegulPept 107: 63-69.
- Wierup N, Sundler F (2004) Circulating levels of ghrelin in human fetuses. Eur J Endocrinol 150: 405.
- Kailey B, van de Bunt M, Cheley S, Johnson PR, MacDonald PE,et al. (2012) SSTR2 is the functionally dominant somatostatin receptor in human pancreatic beta- and alpha-cells. Am J PhysiolEndocrinolMetab 303: 1107-1116.
- Braun M (2014) The somatostatin receptor in human pancreatic beta-cells. VitamHorm 95: 165-193.
- Brereton MF, Vergari E, Zhang Q, Clark A (2015) Alpha, Delta and PP-cells: Are they the architectural cornerstones of islet structure and co-ordination? J HistochemCytochem 63: 575-591.
- Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, et al. (2006) The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. ProcNatlAcadSci U S A 103: 2334-2339.
- Roder PV, Wu B, Liu Y, Han W (2016) Pancreatic regulation of glucose homeostasis. ExpMol Med 48: e219.
- Bonner-Weir S, Orci L (1982) New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes 31: 883-889.
- Henderson JR, Moss MC (1985) A morphometric study of the endocrine and exocrine capillaries of the pancreas. Q J ExpPhysiol 70: 347-356.
- Olsson R, Carlsson PO (2006) The pancreatic islet endothelial cell: emerging roles in islet function and disease. Int J Biochem Cell Biol 38: 710-714.
- Cao Z, Wang X (2014) The endocrine role between beta cells and intra-islet endothelial cells. Endocr J 61: 647-654.
- Zeng W, Gouw AS, van den Heuvel MC, Zwiers PJ, Zondervan PE, et al. (2008) The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology 48: 1517-1527.
- Bellacen K, Kalay N, Ozeri E, Shahaf G, Lewis EC, et al. (2013) Revascularization of pancreatic islet allografts is enhanced by alpha-1-antitrypsin under anti-inflammatory conditions. Cell Transplant 22: 2119-2133.
- Jiang X, Abiatari I, Kong B, Erkan M, De Oliveira T, et al. (2009) Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer. Pancreatology 9: 165-172.
- Jansson L, Carlsson PO (2002) Graft vascular function after transplantation of pancreatic islets. Diabetologia 45: 749-763.
- Menger MD, Yamauchi J, Vollmar B (2001) Revascularization and microcirculation of freely grafted islets of Langerhans. World J Surg 25: 509-515.
- Mattsson G, Jansson L, Carlsson PO (2002) Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes 51: 1362-1366.
- Carlsson PO, Palm F, Andersson A, Liss P (2001) Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 50: 489-495.
- Lau J, Carlsson PO (2009) Low revascularization of human islets when experimentally transplanted into the liver. Transplantation 87: 322-325.
- Zhao M, Choudhary P, Srinivasan P, Tang H, Heaton N, et al. (2015) Modification of human islet preparation: an effective approach to improve graft outcome after islet transplantation? HormMetab Res 47: 72-77.
- Konstantinova I, Lammert E (2004) Microvascular development: learning from pancreatic islets. Bioessays 26: 1069-1075.
- Lukinius A, Jansson L, Korsgren O (1995) Ultrastructural evidence for blood microvessels devoid of an endothelial cell lining in transplanted pancreatic islets. Am J Pathol 146: 429-435.
- Nyqvist D, Speier S, Rodriguez-Diaz R, Molano RD, Lipovsek S, et al. (2011) Donor islet endothelial cells in pancreatic islet revascularization. Diabetes 60: 2571-2577.
- Kampf C, Mattsson G, Carlsson PO (2006) Size-dependent revascularization of transplanted pancreatic islets. Cell Transplant 15: 205-209.
- Johansson U, Rasmusson I, Niclou SP, Forslund N, Gustavsson L, et al. (2008) Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization. Diabetes 57: 2393-2401.
- Ilgun H, Kim JW, Luo L (2015) Adult stem cells and diabetes therapy. J Stem Cell Res Transplant.
- Rackham CL, Dhadda PK, Le Lay AM, King AJ, Jones PM, et al. (2014) Preculturing islets with adipose-derived mesenchymal stromal cells is an effective strategy for improving transplantation efficiency at the clinically preferred intraportal site. Cell Med 7: 37-47.
- Fransson M, Brannstrom J, Duprez I, Essand M, Le Blanc K, et al. (2015) Mesenchymal stromal cells support endothelial cell interactions in an intramuscular islet transplantation model. Regen Med Res 3: 1.
- Cantaluppi V, Biancone L, Figliolini F, Beltramo S, Medica D, et al. (2012) Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets. Cell Transplant 21: 1305-1320.
- Kaufman-Francis K, Koffler J, Weinberg N, Dor Y, Levenberg S, et al. (2012) Engineered vascular beds provide key signals to pancreatic hormone-producing cells. PLoS One 7: e40741.
- Phelps EA, Templeman KL, Thule PM, Garcia AJ (2015) Engineered VEGF-releasing PEG-MAL hydrogel for pancreatic islet vascularization. Drug DelivTransl Res 5: 125-136.
- Amer LD, Mahoney MJ, Bryant SJ (2014) Tissue engineering approaches to cell-based type 1 diabetes therapy. Tissue Eng Part B Rev 20: 455-467.
- Willenberg BJ, Oca-Cossio J, Cai Y, Brown AR, Clapp WL, et al. (2015) Repurposed biological scaffolds: kidney to pancreas. Organogenesis 11: 47-57.
- Linn T, Schneider K, Hammes HP, Preissner KT, Brandhorst H, et al. (2003) Angiogenic capacity of endothelial cells in islets of Langerhans. FASEB J 17: 881-883.
- Nyqvist D, Kohler M, Wahlstedt H, Berggren PO (2005) Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. Diabetes 54: 2287-2293.
- Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803.
- Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006)VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
- Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70.
- Patel-Hett S, D'Amore PA (2011) Signal transduction in vasculogenesis and developmental angiogenesis. Int J DevBiol 55:353-363.
- Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, et al. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
- Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629-5632.
- Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50: 1774-1778.
- Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, et al. (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312.
- Lobb RR, Key ME, Alderman EM, Fett JW (1985) Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line. Int J Cancer 36: 473-478.
- Bruce JN, Criscuolo GR, Merrill MJ, Moquin RR, Blacklock JB, et al.(1987) Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg 67: 880-884.
- Criscuolo GR, Merrill MJ, Oldfield EH (1988) Further characterization of malignant glioma-derived vascular permeability factor. Journal of neurosurgery 69: 254-262.
- Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL,et al. (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470-1478.
- Rosenthal RA, Megyesi JF, Henzel WJ, Ferrara N, Folkman J (1990) Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 4: 53-59.
- Clauss M, Gerlach M, Gerlach H, Brett J, Wang F,et al. (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J Exp Med 172: 1535-1545.
- Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
- Houck KA, Ferrara N, Winer J, Cachianes G, Li B, et al. (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. MolEndocrinol 5: 1806-1814.
- Suto K, Yamazaki Y, Morita T, Mizuno H (2005) Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J BiolChem 280: 2126-2131.
- Patan S (2000) Vasculogenesis and angiogenesis as mechanisms of vascular network formation growth and remodeling. J Neurooncol 50: 1-15.
- Benjamin LE, Keshet E (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. ProcNatlAcadSci USA 94: 8761-8766.
- Gerber HP, Dixit V, Ferrara N (1998)Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J BiolChem 273: 13313-13316.
- Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulatesecNOS message protein and NO production in human endothelial cells. Am J Physiol 274: H1054-1058.
- Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26: 943-954.
- Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
- Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, et al. (1996) Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J BiolChem 271: 19310-19317.
- Aase K, von Euler G, Li X, Ponten A, Thoren P, et al. (2001)Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104: 358-364.
- Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, et al. (2000) Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 86: E29-35.
- Saharinen P, Tammela T, Karkkainen MJ, Alitalo K (2004) Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25: 387-395.
- Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K, et al. (1998) Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J BiolChem 273: 8413-8418.
- Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J,et al. (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5: 74-80.
- Tammela T, Alitalo K (2010) Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476.
- Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, et al. (1998) Vascular endothelial growth factor C induces angiogenesis in vivo. ProcNatlAcadSci USA 95: 14389-14394.
- Akahane M, Akahane T, Matheny SL, Shah A, Okajima E, et al. (2006) Vascular endothelial growth factor-D is a survival factor for human breast carcinoma cells. Int J Cancer 118: 841-849.
- LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, et al. (2001) Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412: 877-874.
- Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, et al. (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18: 363-374.
- Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. ProcNatlAcadSci USA 88: 9267-9271.
- Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
- Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J ClinOncol 20: 4368-4380.
- Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends BiochemSci 28: 488-494.
- Zachary I, Gliki G (2001) Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 49: 568-581.
- Gerber HP, Condorelli F, Park J, Ferrara N (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes Flt-1 but not Flk-1/KDR is up-regulated by hypoxia. J BiolChem 272: 23659-23667.
- Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A,et al. (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343.
- Clauss M, Weich H, Breier G, Knies U, Rockl W, et al. (1996) The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J BiolChem 271: 17629-17634.
- Lyden D, Hattori K, Dias S, Costa C, Blaikie P, et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201.
- Chen WS, Kitson RP, Goldfarb RH (2002) Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1) In Vivo 16: 439-445.
- Matsumoto T, Claesson-Welsh L (2001) VEGF receptor signal transduction. Sci STKE 2001: re21.
- Takahashi T, Yamaguchi S, Chida K, Shibuya M (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20: 2768-2778.
- Partanen TA, Alitalo K, Miettinen M (1999) Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86: 2406-2412.
- Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, et al. (2004) Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 94: 984-992.
- Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G, et al. (1998) A common precursor for hematopoietic and endothelial cells. Development 125: 725-732.
- Yamaguchi TP, Dumont DJ, Conlon RA, Breitman ML, Rossant J, et al. (1993) Flk-1 anflt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development 118: 489-498.
- Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, et al. (2012) Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 484: 110-114.
- Veikkola T, Lohela M, Ikenberg K, Makinen T, Korff T, et al. (2003) Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J 17: 2006-2013.
- Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K, et al. (2000) Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156: 1499-1504.
- Benedito R, Roca C, Sorensen I, Adams S, Gossler A, et al. (2009) The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137: 1124-1135.
- Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, et al. (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445: 776-780.
- Siekmann AF, Lawson ND (2007) Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature 445: 781-784.
- Suchting S, Freitas C, le Noble F, Benedito R, Breant C, et al. (2007) The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. ProcNatlAcadSci USA 104: 3225-3230.
- Gridley T (2007) Vascular biology: vessel guidance. Nature 445: 722-723.
- Hofmann JJ, Iruela-Arispe ML (2007) Notch signaling in blood vessels: who is talking to whom about what? Circ Res 100: 1556-1568.
- Roca C, Adams RH (2007) Regulation of vascular morphogenesis by notch signaling. Genes Dev 21: 2511-2524.
- Claxton S, Fruttiger M (2004) Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr Patterns 5: 123-127.
- Favre CJ, Mancuso M, Maas K, McLean JW, Baluk P, et al. (2003) Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. Am J Physiol Heart CircPhysiol 285: H1917-1938.
- Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, et al. (2001) Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. MechDev 108: 161-164.
- Dou GR, Wang YC, Hu XB, Hou LH, Wang CM,et al. (2008) RBP-J the transcription factor downstream of Notch receptors is essential for the maintenance of vascular homeostasis in adult mice. FASEB J 22: 1606-1617.
- Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M, et al. (2004) The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev 18: 901-911.
- Iso T, Chung G, Hamamori Y, Kedes L (2002) HERP1 is a cell type-specific primary target of Notch. J BiolChem 277: 6598-6607.
- Taylor KL, Henderson AM, Hughes CC (2002) Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc Res 64: 372-383.
- Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, et al. (2006) Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. FASEB J 20: 1009-1011.
- Krebs LT, Deftos ML, Bevan MJ, Gridley T (2001) The Nrarp gene encodes an ankyrin-repeat protein that is transcriptionally regulated by the notch signaling pathway. DevBiol 238: 110-119.
- Phng LK, Potente M, Leslie JD, Babbage J, Nyqvist D, et al. (2009) Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev Cell 16: 70-82.
- Phng LK, Gerhardt H (2009) Angiogenesis: A team effort coordinated by notch. Dev Cell 16: 196-208.
- Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson S L, et al. (2007) Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134: 839-844.
- Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, et al. (2007) Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. ProcNatlAcadSci USA 104: 3219-3224.
- Benedito R, Trindade A, Hirashima M, Henrique D, da Costa LL, et al. (2008) Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC DevBiol 8: 117.
- Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, et al. (2008) Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood 112: 1720-1729.
- Noseda M, Chang L, McLean G, Grim JE, Clurman BE,et al. (2004) Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 24: 8813-8822.
- Hodkinson PS, Elliott PA, Lad Y, McHugh BJ, MacKinnon AC, et al. (2007) Mammalian NOTCH-1 activates beta1 integrins via the small GTPase R-Ras. J BiolChem 282: 28991-29001.
- Harrington LS, Sainson RC, Williams CK, Taylor JM, Shi W, et al. (2008) Regulation of multiple angiogenic pathways by dll4 and notch in human umbilical vein endothelial cells. Microvasc Res 75: 144-154.
- Leong KG, Hu X, Li L, Noseda M, Larrivee B, et al. (2002) Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Biol 22: 2830-2841.
- Horowitz A, Simons M (2009) Branching morphogenesis. Circ Res 103: 784-795.
- Blancas AA, Wong LE, Glaser DE, McCloskey KE (2013) Specialized tip/stalk-like and phalanx-like endothelial cells from embryonic stem cells. Stem Cells Dev 22: 1398-1407.
- De Smet F, Segura I, De Bock K, Hohensinner PJ, Carmeliet P, et al. (2009) Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. ArteriosclerThrombVascBiol 29: 639-649.
- Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, et al. (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136: 839-851.
- Eilken HM, Adams RH (2010) Dynamics of endothelial cell behavior in sprouting angiogenesis. CurrOpin Cell Biol 22: 617-625.
- Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, et al. (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161: 1163-1177.
- Lu X, Le Noble F, Yuan L, Jiang Q, De Lafarge B, et al. (2004) The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature 432: 179-186.
- Thurston G, Kitajewski J (2008) VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 99: 1204-1209.
- Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, et al. (2002) Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16: 2684-2698.
- Chappell JC, Bautch VL (2010) Vascular development: genetic mechanisms and links to vascular disease. Curr Top DevBiol 90: 43-72.
- Chappell JC, Taylor SM, Ferrara N, Bautch VL (2009) Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 17: 377-386.
- Shawber CJ, Funahashi Y, Francisco E, Vorontchikhina M, Kitamura Y, et al. (2007) Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest 117: 3369-3382.
- Kume T (2009) Novel insights into the differential functions of Notch ligands in vascular formation. J Angiogenes Res 1: 8.
- Zhang P, Yan X, Chen Y, Yang Z, Han H, et al. (2014) Notch signaling in blood vessels: from morphogenesis to homeostasis. Sci China Life Sci 57: 774-780.
- Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, et al. (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23: 14-25.
- Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745.
- Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, et al. (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454: 656-60.
- Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, et al. (2008) A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res 68: 4727-4735.
- Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, et al. (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083-1087.
- Williams CK, Li JL, Murga M, Harris AL, Tosato G, et al. (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107: 931-939.
- Stone J, Itin A, Alon T, Pe'Er J, Gnessin H, et al. (1995) Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. The Journal of neuroscience 15: 4738-4747.
- Lawson ND, Vogel AM, Weinstein BM (2002) Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 3: 127-136.
- Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, et al. (2005) Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65: 8690-8697.
- Zhang J, Liu M, Su Y, Du J, Zhu AJ, et al. (2012) A targeted in vivo RNAI screen reveals deubiquitinases as new regulators of Notch signaling. G3 (Bethesda) 2: 1563-1575.
- Fang L, Choi SH, Baek JS, Liu C, Almazan F, et al. (2013) Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature 498: 118-122.
- Avraham-Davidi I, Ely Y, Pham VN, Castranova D, Grunspan M, et al. (2012) ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1. Nat Med 18: 967-973.
- Angius F, Uda S, Piras E, Spolitu S, Ingianni A, et al. (2012) Neutral lipid alterations in human herpesvirus 8-infected HUVEC cells and their possible involvement in neo-angiogenesis. BMC Microbiol 15: 74.
- Sacilotto N, Chouliaras KM, Nikitenko LL, Lu YW, Fritzsche M,et al. (2016) MEF2 transcription factors are key regulators of sprouting angiogenesis. Genes Dev 30: 2297-2309.
- Spuul P, Daubon T, Pitter B, Alonso F, Fremaux I, et al. (2016) VEGF-A/Notch-Induced PodosomesProteolyse Basement Membrane Collagen-IV during Retinal Sprouting Angiogenesis. Cell Rep 17: 484-500.
- Harjes U, Bridges E, McIntyre A, Fielding BA, Harris AL, et al. (2014) Fatty acid-binding protein 4 a point of convergence for angiogenic and metabolic signaling pathways in endothelial cells. J BiolChem 289: 23168-23176.
- Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquiere B, et al. (2014) Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab 19: 37-48.
- De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, et al. (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154: 651-663.
- Wilhelm K, Happel K, Eelen G, Schoors S, Oellerich MF, et al. (2016) FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature 529: 216-220.
- Lee DC, Sohn HA, Park ZY, Oh S, Kang YK, et al. (2015) A lactate-induced response to hypoxia. Cell 161: 595-609.
- Kang DH, Lee DJ, Lee KW, Park YS, Lee JY, et al. (2011) Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell 44: 545-558.
- Panieri E, Santoro MM (2015) ROS signaling and redox biology in endothelial cells. Cell Mol Life Sci 72: 3281-3303.
- Warren CM, Ziyad S, Briot A, Der A, Iruela-Arispe ML, et al. (2014) A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes. Sci Signal 7: 1.
- Goetz JG, Steed E, Ferreira RR, Roth S, Ramspacher C, et al. (2014) Endothelial cilia mediate low flow sensing during zebrafish vascular development. Cell Rep 6: 799-808.
- Dinsmore C, Reiter JF (2016) Endothelial primary cilia inhibit atherosclerosis. EMBO Rep 17: 156-166.
- Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671-674.
- Patan S (2004) Vasculogenesis and angiogenesis. Cancer Treat Res 117: 3-32.
- Karamysheva AF (2008) Mechanisms of angiogenesis. Biochemistry (Mosc) 73: 751-762.
- Brissova M, Fowler M, Wiebe P, Shostak A, Shiota M, et al. (2004) Intraislet endothelial cells contribute to revascularization of transplanted pancreatic islets. Diabetes 53: 1318-1325.
- Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, et al. (2006) Pancreatic islet production of vascular endothelial growth factor--a is essential for islet vascularization, revascularization and function. Diabetes 55: 2974-2985.
- Ausprunk DH, Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14: 53-65.
- Fruttiger M (2007) Development of the retinal vasculature. Angiogenesis 10: 77-88.
- Lawson ND, Weinstein BM (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish. DevBiol 248: 307-318.
- Bayless KJ, Davis GE (2002) The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. J Cell Sci 115: 1123-1136.
- Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, et al. (2003)Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res 66: 102-112.
- Reinert RB, Brissova M, Shostak A, Pan FC, Poffenberger G, et al. (2013) Vascular endothelial growth factor-a and islet vascularization are necessary in developing but not adult pancreatic islets. Diabetes 62: 4154-4164.
- Virtanen I, Banerjee M, Palgi J, Korsgren O, Lukinius A, et al. (2008) Blood vessels of human islets of Langerhans are surrounded by a double basement membrane. Diabetologia 51: 1181-1191.
- Brissova M, Shostak A, Fligner CL, Revetta FL, Washington MK, et al. (2015) Human islets have fewer blood vessels than mouse islets and the density of islet vascular structures is increased in type 2 diabetes. J HistochemCytochem 63: 637-645.
- Cai Q, Brissova M, Reinert RB, Pan FC, Brahmachary P, et al. (2012) Enhanced expression of VEGF-A in beta cells increases endothelial cell number but impairs islet morphogenesis and beta cell proliferation. DevBiol 367: 40-54.
- Watada H (2010) Role of VEGF-A in pancreatic beta cells. Endocr J 57: 185-191.
- Lammert E, Cleaver O, Melton D (2001) Induction of pancreatic differentiation by signals from blood vessels. Science 294: 564-567.
- Yoshitomi H, Zaret KS (2004) Endothelial cell interactions initiate dorsal pancreas development by selectively inducing the transcription factor Ptf1a. Development 131: 807-817.
- Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, et al. (2004) Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 53: 963-970.